Comparative effectiveness of switching paroxetine formulation for treatment of major depressive disorder: an open-label multicenter study

Tempei Otsubo,1 Yoshinori Watanabe,2,3 Seiji Hongo,3 Mikichika Inoue,4 Kimiko Akimoto,4 Ken Murakami,5 Ryutaro Takahashi,6 Toshiaki Kikuchi7 1Department of Psychiatry, Tokyo Women’s Medical University Medical Center East, Tokyo, Japan; 2Himorogi Psychiatric Institute, Tokyo, Japan; 3Nanko...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Otsubo T, Watanabe Y, Hongo S, Inoue M, Akimoto K, Murakami K, Takahashi R, Kikuchi T
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	major depressive disorder controlled-release paroxetine drug formulation antidepressant switching Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/20da93dc94904d95baef838f0972b627
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:20da93dc94904d95baef838f0972b627
record_format	dspace
spelling	oai:doaj.org-article:20da93dc94904d95baef838f0972b6272021-12-02T02:05:20ZComparative effectiveness of switching paroxetine formulation for treatment of major depressive disorder: an open-label multicenter study1178-2021https://doaj.org/article/20da93dc94904d95baef838f0972b6272018-04-01T00:00:00Zhttps://www.dovepress.com/comparative-effectiveness-of-switching-paroxetine-formulation-for-trea-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Tempei Otsubo,1 Yoshinori Watanabe,2,3 Seiji Hongo,3 Mikichika Inoue,4 Kimiko Akimoto,4 Ken Murakami,5 Ryutaro Takahashi,6 Toshiaki Kikuchi7 1Department of Psychiatry, Tokyo Women’s Medical University Medical Center East, Tokyo, Japan; 2Himorogi Psychiatric Institute, Tokyo, Japan; 3Nanko Clinic of Psychiatry, Shirakawa, Japan; 4Ikebukuro Internal Medicine, Tokyo, Japan; 5Murakami Hospital, Tokyo, Japan; 6Takahashi Clinic, Tokyo, Japan; 7Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan Aim: To assess the effectiveness and safety of switching the antidepressant formulation from immediate-release (IR) to controlled-release (CR) paroxetine in patients with major depressive disorder (MDD). Patients and methods: A total of 113 outpatients with MDD diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, and treated with a stable dose of IR paroxetine for at least 6 months were enrolled. Patients were then switched to CR paroxetine for 8 weeks. Effectiveness was evaluated by scores on the Himorogi Self-Rating Depression/Anxiety Scales (HSDS/HSAS) and the Clinical Global Impression – Severity (CGI-S). Safety was evaluated based on the reported adverse drug reactions (ADRs). Medication satisfaction and preference were assessed based on questionnaire responses using Likert-type scales. Results: The overall patient HSDS/HSAS scores significantly improved after switching from IR to CR paroxetine (P<0.001). Furthermore, CR paroxetine was superior to IR paroxetine (P<0.001) according to the results of the CGI-S evaluation. ADRs were experienced by 14 (12.4%) patients, including dry mouth, nausea/vomiting, somnolence/drowsiness, and wakefulness/arousal during sleep. Satisfaction and preference for paroxetine improved after switching to the CR formulation (P<0.001; chi-square test). Conclusion: These results suggest that switching the treatment from IR to CR paroxetine could improve depressive symptoms and decrease ADRs. However, these results may have been caused by the psychological effect of drug switching. Hence, future studies with blinded evaluation methods are required to confirm and expand our findings. Keywords: depression, controlled-release paroxetine, drug formulation, antidepressant, immediate-releaseOtsubo TWatanabe YHongo SInoue MAkimoto KMurakami KTakahashi RKikuchi TDove Medical Pressarticlemajor depressive disordercontrolled-release paroxetinedrug formulationantidepressantswitchingNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 14, Pp 955-966 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	major depressive disorder controlled-release paroxetine drug formulation antidepressant switching Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	major depressive disorder controlled-release paroxetine drug formulation antidepressant switching Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Otsubo T Watanabe Y Hongo S Inoue M Akimoto K Murakami K Takahashi R Kikuchi T Comparative effectiveness of switching paroxetine formulation for treatment of major depressive disorder: an open-label multicenter study
description	Tempei Otsubo,1 Yoshinori Watanabe,2,3 Seiji Hongo,3 Mikichika Inoue,4 Kimiko Akimoto,4 Ken Murakami,5 Ryutaro Takahashi,6 Toshiaki Kikuchi7 1Department of Psychiatry, Tokyo Women’s Medical University Medical Center East, Tokyo, Japan; 2Himorogi Psychiatric Institute, Tokyo, Japan; 3Nanko Clinic of Psychiatry, Shirakawa, Japan; 4Ikebukuro Internal Medicine, Tokyo, Japan; 5Murakami Hospital, Tokyo, Japan; 6Takahashi Clinic, Tokyo, Japan; 7Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan Aim: To assess the effectiveness and safety of switching the antidepressant formulation from immediate-release (IR) to controlled-release (CR) paroxetine in patients with major depressive disorder (MDD). Patients and methods: A total of 113 outpatients with MDD diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, and treated with a stable dose of IR paroxetine for at least 6 months were enrolled. Patients were then switched to CR paroxetine for 8 weeks. Effectiveness was evaluated by scores on the Himorogi Self-Rating Depression/Anxiety Scales (HSDS/HSAS) and the Clinical Global Impression – Severity (CGI-S). Safety was evaluated based on the reported adverse drug reactions (ADRs). Medication satisfaction and preference were assessed based on questionnaire responses using Likert-type scales. Results: The overall patient HSDS/HSAS scores significantly improved after switching from IR to CR paroxetine (P<0.001). Furthermore, CR paroxetine was superior to IR paroxetine (P<0.001) according to the results of the CGI-S evaluation. ADRs were experienced by 14 (12.4%) patients, including dry mouth, nausea/vomiting, somnolence/drowsiness, and wakefulness/arousal during sleep. Satisfaction and preference for paroxetine improved after switching to the CR formulation (P<0.001; chi-square test). Conclusion: These results suggest that switching the treatment from IR to CR paroxetine could improve depressive symptoms and decrease ADRs. However, these results may have been caused by the psychological effect of drug switching. Hence, future studies with blinded evaluation methods are required to confirm and expand our findings. Keywords: depression, controlled-release paroxetine, drug formulation, antidepressant, immediate-release
format	article
author	Otsubo T Watanabe Y Hongo S Inoue M Akimoto K Murakami K Takahashi R Kikuchi T
author_facet	Otsubo T Watanabe Y Hongo S Inoue M Akimoto K Murakami K Takahashi R Kikuchi T
author_sort	Otsubo T
title	Comparative effectiveness of switching paroxetine formulation for treatment of major depressive disorder: an open-label multicenter study
title_short	Comparative effectiveness of switching paroxetine formulation for treatment of major depressive disorder: an open-label multicenter study
title_full	Comparative effectiveness of switching paroxetine formulation for treatment of major depressive disorder: an open-label multicenter study
title_fullStr	Comparative effectiveness of switching paroxetine formulation for treatment of major depressive disorder: an open-label multicenter study
title_full_unstemmed	Comparative effectiveness of switching paroxetine formulation for treatment of major depressive disorder: an open-label multicenter study
title_sort	comparative effectiveness of switching paroxetine formulation for treatment of major depressive disorder: an open-label multicenter study
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/20da93dc94904d95baef838f0972b627
work_keys_str_mv	AT otsubot comparativeeffectivenessofswitchingparoxetineformulationfortreatmentofmajordepressivedisorderanopenlabelmulticenterstudy AT watanabey comparativeeffectivenessofswitchingparoxetineformulationfortreatmentofmajordepressivedisorderanopenlabelmulticenterstudy AT hongos comparativeeffectivenessofswitchingparoxetineformulationfortreatmentofmajordepressivedisorderanopenlabelmulticenterstudy AT inouem comparativeeffectivenessofswitchingparoxetineformulationfortreatmentofmajordepressivedisorderanopenlabelmulticenterstudy AT akimotok comparativeeffectivenessofswitchingparoxetineformulationfortreatmentofmajordepressivedisorderanopenlabelmulticenterstudy AT murakamik comparativeeffectivenessofswitchingparoxetineformulationfortreatmentofmajordepressivedisorderanopenlabelmulticenterstudy AT takahashir comparativeeffectivenessofswitchingparoxetineformulationfortreatmentofmajordepressivedisorderanopenlabelmulticenterstudy AT kikuchit comparativeeffectivenessofswitchingparoxetineformulationfortreatmentofmajordepressivedisorderanopenlabelmulticenterstudy
_version_	1718402697170780160

Comparative effectiveness of switching paroxetine formulation for treatment of major depressive disorder: an open-label multicenter study

Ejemplares similares